pyrazines has been researched along with Brill-Symmers Disease in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (26.67) | 29.6817 |
| 2010's | 22 (73.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fayad, L; Fowler, N; Jain, P; Kanagal-Shamanna, R; Medeiros, LJ; Nastoupil, L; Oki, Y; Romaguera, J; San Lucas, FA; Wang, M; Westin, JR | 1 |
| Andorsky, DJ; Assouline, S; Forero-Torres, A; Jones, V; Klein, LM; Kolibaba, KS; Patel-Donnelly, D; Sharman, JP; Shi, W; Smith, M; Yasenchak, CA; Ye, W | 1 |
| Cakana, A; Coiffier, B; Crump, M; de Vos, S; Elsayed, YA; Esseltine, DL; Favis, R; Gaffney, D; Henitz, ED; Hong, X; Karkera, JD; Li, W; Mayer, J; Mulligan, G; Offner, F; Osmanov, EA; Ricci, D; Romejko-Jarosinska, J; Rule, S; Schaffer, ME; Scheliga, A; Shapiro, A; Shpilberg, O; Teixeira, A; Theocharous, P; van de Velde, H; Zinzani, PL | 1 |
| Barton, MK | 1 |
| Alinari, L; Baiocchi, RA; Blum, KA; Byrd, JC; Johnston, JS; Li, X; Lin, TS; Lustberg, ME; Porcu, P | 1 |
| Blum, KA; Maddocks, K | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Cabanillas, F; Chen, CS; Craig, M; Esseltine, DL; Hanna, WT; Neuwirth, R; O'Connor, OA | 1 |
| Li, YL | 1 |
| Cheson, BD | 2 |
| Cortelli, BM; Dumitrescu, O; Gerecitano, J; Hamelers, R; Hamlin, P; Lin, D; Moskowitz, C; Neylon, E; O'Connor, OA; Pappanicholaou, J; Portlock, C; Sarasohn, D; Straus, D; Wright, J; Zelenetz, AD; Zhang, Z | 1 |
| Belt, R; Boral, AL; Dakhil, SR; de Vos, S; Flowers, CR; Glenn, M; Goy, A; Gregory, SA; Hart, L; Holladay, C; Knapp, M; McLaughlin, P; Patel-Donnelly, D; Saleh, MN; Zhang, T | 1 |
| Beguin, Y; Bonnet, C; de Leval, L; Deprijck, B; Fillet, G | 1 |
| Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Evens, AM; Gerecitano, J; Gonen, M; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, J; Zelenetz, AD | 1 |
| Bhende, PM; Damania, B; Dittmer, DP; Lim, MS; Park, SI | 1 |
| Agathocleous, A; Hunter, H; Johnson, P; Kerr, JP; Lister, A; Matthews, J; Montoto, S; Neeson, SM; Radford, J; Rohatiner, A; Rule, S; Strauss, S | 1 |
| Dreyling, M | 1 |
| Tomás, JF | 1 |
| Coiffier, B; Crump, M; de Vos, S; Elsayed, YA; Enny, C; Esseltine, DL; Hong, X; Mayer, J; Offner, F; Osmanov, EA; Rule, S; Scheliga, A; Shpilberg, O; Teixeira, A; Theocharous, P; van de Velde, H; Walewski, J; Zhu, E; Zinzani, PL | 1 |
| Basi, S; Cantin, G; Chen, BE; Couban, S; Crump, M; Djurfeldt, M; Gascoyne, RD; Imrie, K; Lemieux, B; MacDonald, D; Rubin, S; Rubinger, M; Sehn, LH; Shepherd, L; Sussman, J | 1 |
| Amin, B; Cashen, AF; Cheson, BD; Fowler, N; Jacobs, SA; Kahl, BS; Lee, P; Letzer, J; Matous, JV; Parasuraman, S; Rosen, P; Saleh, A; Shi, H; Smith, S; Williams, ME | 1 |
| Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M | 1 |
| Kimby, E | 1 |
| Buckstein, R; Caballero, D; Coiffier, B; Elsayed, YA; Enny, C; Esseltine, DL; Garicochea, B; Khuageva, NK; Soubeyran, P; Theocharous, P; Van Hoof, A; Walewski, J; Wang, H; Zhu, E; Zinzani, PL | 1 |
| Bosly, A; Bouabdallah, R; Boue, F; Bron, D; Casasnovas, O; Coiffier, B; Delarue, R; Feugier, P; Haioun, C; Offner, F; Ribrag, V; Tilly, H | 1 |
| O'Connor, OA | 1 |
| Coleman, M; Furman, RR; Leonard, JP | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Nguyen, CA; Romaguera, J; Wang, M; Zhang, L; Zhou, Y | 1 |
9 review(s) available for pyrazines and Brill-Symmers Disease
| Article | Year |
|---|---|
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
[Current treatment of follicular lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Prednisone; Prognosis; Pyrazines; Radioimmunotherapy; Radiotherapy, Adjuvant; Risk Factors; Rituximab; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine | 2009 |
[Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ki-1 Antigen; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precision Medicine; Prognosis; Pyrazines; Risk Factors; Rituximab; Survival Rate; Waldenstrom Macroglobulinemia | 2011 |
New agents in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment | 2011 |
Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Lenalidomide; Lymphoma, Follicular; Pyrazines; Rituximab; Thalidomide; Tumor Microenvironment | 2012 |
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Multicenter Studies as Topic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Pyrazines; Waldenstrom Macroglobulinemia | 2006 |
13 trial(s) available for pyrazines and Brill-Symmers Disease
| Article | Year |
|---|---|
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Proteins; Pyrazines; Syk Kinase; Waldenstrom Macroglobulinemia | 2019 |
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Mice; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Proteasome Inhibitors; Pyrazines; Receptors, IgG; Recurrence; Rituximab; Treatment Outcome | 2011 |
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2014 |
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Protease Inhibitors; Pyrazines | 2009 |
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Feasibility Studies; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Rituximab; Treatment Outcome | 2009 |
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia | 2010 |
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Infusion Pumps; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Rituximab; Young Adult | 2011 |
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Cyclophosphamide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2011 |
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neural Conduction; Prednisone; Pyrazines; Rituximab; Vincristine | 2012 |
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Rituximab | 2012 |
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Salvage Therapy; Survival Rate | 2013 |
8 other study(ies) available for pyrazines and Brill-Symmers Disease
| Article | Year |
|---|---|
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Disease Progression; Drug Resistance; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome | 2018 |
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Heterozygote; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Sequence Analysis, DNA; Treatment Outcome; Young Adult | 2013 |
Predictive biomarkers may help individualize treatment for patients with follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Humans; Lymphoma, Follicular; Precision Medicine; Proteasome Endopeptidase Complex; Pyrazines; Rituximab | 2013 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
[Analysis of bortezomib treatment efficacy and adverse reactions for patients with follicular lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Epirubicin; Humans; Lymphoma, Follicular; Prednisolone; Pyrazines; Treatment Outcome; Vincristine | 2015 |
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine | 2008 |
The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Female; Forkhead Transcription Factors; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lymphoma, Follicular; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
The challenge of recurrent follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Follicular; Male; Pyrazines; Rituximab | 2011 |